Brief: ADDvise Expects Return To Growth After Launching New Products
April 18 (Reuters) - ADDvise Group AB (publ) ADDVa.ST :
* LAB SEGMENT DELIVERED STRONG ORGANIC GROWTH WHEREAS OUR
PHARMACEUTICALS BUSINESS AFFECTED GROUP NEGATIVELY
* CHANGING PRODUCT MIX RESULTED IN LOWER MARGINS
* WE ARE IN THE PROCESS OF LAUNCHING SEVERAL NEW DRUGS WHICH
WE
EXPECT WILL DRIVE A RETURN TO GROWTH WITHIN THE PRODUCT CATEGORY
Source text for Eikon: ID:nWkr65X6VS
Further company coverage: ADDVa.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on ADDvise AB (publ)
See all newsBrief: Addvise Proposes That No Dividend Be Paid For 2025
Brief: ADDvise CFO Sells SEK 1.1 Million Of Shares In Co
Sweden's ADDvise Q4 prelim revenue misses estimates
Brief: ADDvise Group Q4 Sales SEK 422 Million
Brief: Statement From Independent Bid Committee Of Addvise In Relation To Public Offer From Amplex